


PC10925B  
Information Disclosure Statement



Certificate of Mailing (37 C.F.R. §1.8):  
I hereby certify that this correspondence is being deposited with the United States Postal Service as First Class Mail in an envelope addressed to:  
Commissioner for Patents,  
PO Box 1450, Alexandria, VA 22313-1450  
on this 5th day of November 2003.

s/   
Julie Agozino

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

In re the Application of:  
**MANOUSSOS PEOS, ET AL**

Serial No.: 10/678,836

Confirmation No.: To be assigned

Filed: October 3, 2003

For: TROPANE DERIVATIVES USEFUL IN  
THERAPY

Group Art Unit: To be assigned

Examiner: To be assigned

**INFORMATION DISCLOSURE STATEMENT UNDER 37 CFR 1.97(b)**

Commissioner For Patents  
P.O. Box 1450  
Alexandria, VA 22313-1450

Sir:

Pursuant to the duty of disclosure under 37 CFR 1.56, Applicants bring the documents listed on the attached substitute Form PTO-1449 to the attention of the Examiner for consideration in connection with the examination of the above-identified application.

This Information Disclosure Statement is being filed within the period specified in 37 CFR 1.97(b)-i.e., (1) within three months of the filing date of the national application, (2) within three months of the date of entry of the national stage as set forth in 37 CFR 1.491 in an international application, or (3) to the undersigned's knowledge, before the mailing date of a first Office Action on the merits, whichever event occurs last.

Copies of the cited documents AC-AE & AR-AV are enclosed. All of the cited art documents are in the English language.

Copies of the cited documents AA-AB, AF-AQ, & AW are not enclosed, they were previously cited by or submitted to the PTO in Application Serial No. 09/865,590, filed May 25, 2001, upon which the present application relies for priority benefit under 35 USC 120.

It is respectfully requested that the Examiner confirm consideration of the cited documents by initialing the attached substitute Form PTO-1449 and returning a copy of the initialed form to the Applicants.

If any fees are due in connection with the filing of this statement, including the fee set forth in 37 CFR 1.17(p) in the event that the period specified in 37 CFR 1.97(b) has elapsed, please charge all required fees to Deposit Account No. 500329.

Respectfully submitted,


Date: Nov. 04, 2003

Keith D. Hutchinson

Keith D. Hutchinson  
Attorney For Applicant  
Registration No. 43,687

Jouron Pharmaceuticals, Inc./A Pfizer Company  
Patent Department  
10777 Science Center Drive  
San Diego, California 92121  
Phone: (858) 526-4608  
Fax: (858) 678-8233

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO		<b>Complete if Known</b>	
		Application Number	10/678,836
		Filing Date	October 3, 2003
		First Named Inventor	Manoussos Perros
		Art Unit	To be assigned
		Examiner Name	To be assigned
		Attorney Docket Number	PC10925B

**U.S. PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	DOCUMENT NUMBER	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear
		Number-Kind Code <sup>2</sup>			
	AA	US 5,968,947	10/19/1999	Zeneca Limited	
	AB	US 6,586,430	07/01/2003	Pfizer, Inc.	

**FOREIGN PATENT DOCUMENTS**

EXAMINER INITIAL	Cite No. <sup>1</sup>	Foreign Patent Document	Publication Date MM-DD-YYYY	Name of Patentee or Applicant of Cited Document	Pages, Columns, Lines, Where Relevant Passages or Relevant Figures Appear	T <sup>6</sup>
		Country Code <sup>3</sup> Number <sup>4</sup> Kind Code <sup>5</sup> (if known)				
	AC	WO 91/11172	08/08/1991	The University of Kansas		
	AD	WO 94/02518	02/03/1994	The University of Kansas		
	AE	WO 98/55148	12/10/1998	Janssen Pharmaceutica N.V.		
	AF	EP 0630887	05/20/1994	Zeneca Limited		
	AG	WO 97/19060	05/29/1997	Zeneca Limited		
	AH	WO 97/24325	07/10/1997	Takeda Chemical Industries Ltd.		
	AI	WO 98/02151	01/22/1998	Leukosite, Inc.		
	AJ	WO 98/25617	06/18/1998	Merck & Co., Inc.		
	AK	WO 98/25604	06/18/1998	Merck & Co., Inc.		
	AL	WO 99/37617	06/18/1998	Merck & Co., Inc.		
	AM	EP 0903349	08/10/1998	F. Hoffmann-La Roche AG		
	AN	WO 99/04794	02/04/1999	Merck & Co., Inc.		

EXAMINER:


DATE CONSIDERED:

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kindof document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.

Under the Paperwork Reduction Act of 1995, no persons are required to respond to a collection of information unless it contains a valid OMB control Number.

Substitute for form 1449/PTO


**INFORMATION DISCLOSURE  
STATEMENT BY APPLICANT**  
(Use as many sheets as necessary)
**Completer if Known**

Application Number	10/678,836
Filing Date	October 3, 2003
First Named Inventor	Manoussos Perros
Art Unit	To be assigned
Examiner Name	To be assigned
Attorney Docket Number	PC10925B

	AO	WO 99/17773	04/15/1999	Smithkline Beecham Corp.	
	AP	WO 99/37619	07/29/1999	Leukosite, Inc.	
	AQ	WO 00/38680	07/06/2000	Pfizer Limited	

**NON PATENT LITERATURE DOCUMENTS**

Examiner Initials	Cite No. <sup>1</sup>	Include name of the author (in CAPITAL LETTERS), title of the article (when appropriate), title of the item (book, magazine, journal, serial, symposium, catalog, etc.), date, page(s), volume-issue number(s), publisher, city and/or country where published.	T <sup>2</sup>
	AR	BERGE, et. al., "Pharmaceutical Salts," <i>Journal of Pharmaceutical Science</i> , 1977, 1-19, Vol 66., No. 1.	
	AS	CASCIERI, et. al., "The Chemokine/Chemokine Receptor Family: Potential and Progress for Therapeutic Intervention," <i>Current Opinion Chem. Biol.</i> 2000, 420-427, Vol. 4, No. 4.	
	AT	COMBADIERE, et. al., "Cloning and Functional Expression of CC CKR5, a Human Monocyte CC Chemokine Receptor Selective for MIP-1 $\alpha$ , MIP-1 $\beta$ , and RANTES," <i>Journal of Leukocyte Biology</i> , 1996, 147-152, Vol. 60.	
	AU	CONNOR, et. al., "VPR Is Required for Efficient Replicaton of Human Immunodeficiency Virus Type-1 in Mononuclear Phagocytes," <i>Virology</i> , 1995, 935-944, Vol. 206, No. 2.	
	AV	DIMITROV, et. al., "Microculture Assay for Isolation of Human Immunodeficiency Virus Type 1 and for Titration of Infected Peripheral Blood Mononuclear Cells," <i>Journal of Clinical Microbiology</i> , 1990, 734-737, Vol 28, No. 4.	
	AW	HESSELGESSER, J., et. al., "Identification and Characterization of Small Molecule Functional Antagonists of the CCR1 Chemokine Receptor," <i>Journal of Biological Chemistry</i> , 1998, 15687-15692, Vol. 273, No. 25.	

1. I have not received the following  
for Application  
AF-AQ

EXAMINER:	DATE CONSIDERED:
-----------	------------------

EXAMINER: Initial if reference considered, whether or not citation is in conformance with MPEP 609. Draw line through citation if not in conformance and not considered. Include copy of this form with next communication to applicant. <sup>1</sup>Applicant's unique citation designation number (optional). <sup>2</sup>See Kinds Codes of USPTO Patent Documents at [www.uspto.gov](http://www.uspto.gov) or MPEP 901.04. <sup>3</sup>Enter Office that issued the document, by the two-letter code (WIPO Standard ST.3). <sup>4</sup>For Japanese patent documents, the indication of the year of the reign of the Emperor must precede the serial number of the patent document. <sup>5</sup>Kind of document by the appropriate symbols as indicated on the document under WIPO Standard ST. 16 if possible. <sup>6</sup>Applicant is to place a check mark here if English language Translation is attached.

This collection of information is required by 37 CFR 1.97 and 1.98. The information is required to obtain or retain a benefit by the public, which is to file (and by the USPTO to process) an application. Confidentiality is governed by 35 U.S.C. 122 and 37 CFR 1.14. This collection is estimated to take 2 hours to complete, including gathering, preparing, and submitting the completed application form to the USPTO. Time will vary depending upon the individual case. Any comments on the amount of time you require to complete this form and/or suggestions for reducing this burden, should be sent to the Chief Information Officer, U.S. Patent and Trademark Office, U.S. Department of Commerce, Washington, D.C. 20231. DO NOT SEND FEES OR COMPLETED FORMS TO THIS ADDRESS. Send to: Commissioner for Patents, P.O. Box 1450, Alexandria, VA 22313-1450.